Pharmafile Logo
Pharmafocus logo
Advanced Search

HCV

Showing 15 posts of 27 posts found.

5204602349_c87b204860_z

FDA warns three Hepatitis C drugs may worsen liver function in some rare cases

August 29, 2019
Medical Communications, Research and Development AbbVie, FDA, Gilead, HCV, MSD, hepatitis C, public health

The FDA has warned that three Hepatitis C (HCV) drugs made by AbbVie, Gilead and MSD are worsening liver function …

News

FDA approves AbbVie’s Mavyret for children with Hepatitis C (HCV)

May 1, 2019
Research and Development AbbVie, HCV, hepatitis C, mavyret, pharma

The FDA has approved AbbVie’s Mavyret tables (glecaprevir/pibrentasvir) as a treatment for hepatitis C (HCV) in children aged 12 to 17 …

News
abbvie_0

AbbVie’s case against the NHS thrown out of court

January 22, 2019
Manufacturing and Production AbbVie, HCV, NHS, health, hepatitis C, public health

A judge has thrown US multinational AbbVie’s case against NHS England’s hepatitis C procurement process, out of court. Mr Justice …

News
hcv_credit_bruceblaus

New hepatitis C combo boasts 97% cure rate for just $300

April 12, 2018
Research and Development AbbVie, DNDi, Drugs for Neglected Diseases initiative, Gilead, HCV, Pharco Pharmaceuticals, hepatitis C, pharma, sovaldi

A partnership of the not-for-profit organisation Drugs for Neglected Diseases initiative (DNDi) and Egyptian drug firm Pharco Pharmaceuticals is working …

News
blood_bags

Contaminated blood inquiry to probe thousands of deaths

July 12, 2017
Medical Communications, Research and Development HCV, HIV, biotech, drugs, haemophilia, pharma, pharmaceutical

UK Government has announced that it will launch an inquiry to discover how 4,670 people were given blood infected by …

News
gilead-sciences

Gilead says US FDA approves Epclusa to treat hepatitis C

June 29, 2016
Research and Development, Sales and Marketing Epclusa, Gilead, HCV, US FDA, drug approval, regulation

US drug firm Gilead Sciences (Nasdaq: GILD) said the US Food and Drug Administration has approved its Epclusa (sofosbuvir/velpatasvir), in …

News
merck-sharp--dohme-corp

Merck says its Zepatier showed better efficacy and safety compared with competition in Phase III trials

April 14, 2016
Research and Development, Sales and Marketing Gilead, HCV, Merck & Co, Zepatier

US pharma giant Merck (NYSE: MRK) on Thursday said late-stage trials for its Zepatier (elbasvir and grazoprevir) to treat chronic …

News
Doctors image

Charity challenges Sovaldi patent

February 10, 2015
Sales and Marketing Gilead, HCV, Médecins du Monde, sofosbuvir, sovaldi, world health organization

Doctors of the World (also known as Médecins du Monde) has filed an opposition to the patent for Gilead’s blockbuster …

News
Gilead image

New drug added to generic Sovaldi licensing

January 26, 2015
Manufacturing and Production, Sales and Marketing Gilead, HCV, hepatitis C, sofosbuvir, sovaldi

Gilead has expanded the licensing of generic versions of its blockbuster hepatitis C treatment Sovaldi to include a new experimental …

News
Harvoni image

Gilead gets Harvoni boost for Europe

November 20, 2014
Sales and Marketing EU, Gilead, HCV, harvoni, hepc, ledipasvir, sofosbuvir, svaldi

Gilead Sciences’ new hepatitis C (HCV) tablet Harvoni has been approved across the European Union to treat the majority of …

News
BMS image

BMS claims advance with hepatitis C regimen

November 10, 2014
Research and Development, Sales and Marketing BMS, Gilead, HCV, dcv-trio, hep C, hepatitis C, liver, sovaldi

Bristol-Myers Squibb has reported data for its hepatitis C virus cocktail that it says outperforms even newer all-oral therapies in …

News
BMS image

BMS pulls hep C combo treatment in US

October 7, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Combo, HCV, asunaprevir, daclatasvir, hep C, sovaldi

Bristol-Myers Squibb will not attempt to bring its new combination hepatitis C treatment to the US market given the current …

News

Sovaldi combo sees CHMP green light

September 29, 2014
Sales and Marketing CHMP, EU, Gilead, HCV, harvoni, hep C, sovaldi

The CHMP is recommending that Gilead’s new combination hepatitis C drug therapy Harvoni should be approved for use across the …

News
BMS image

CHMP approves six drugs including daclatasvir

June 30, 2014
Sales and Marketing BMS, CHMP, HCV, Plavix, daclatasvir, daklinza, ge

A key advisory committee for the European Medicines Agency has given its approval to six new drugs at its latest …

News
boehringer image

Boehringer abandons hep C

June 23, 2014
Research and Development, Sales and Marketing AbbVie, Boehringer, HCV, faldaprevir, german, hep C

Boehringer Ingelheim has abandoned its hepatitis C (HCV) drug development programme as a dead loss after ‘re-evaluating’ its strategy. The …

News

Latest content

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024

ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial

June 25, 2024

GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment

June 24, 2024